Citigroup Raises BeiGene (NASDAQ:BGNE) Price Target to $290.00
BeiGene (NASDAQ:BGNE – Free Report) had its price objective hoisted by Citigroup from $285.00 to $290.00 in a research note released on Thursday morning, Marketbeat.com reports. Citigroup currently has a buy rating on the stock. A number of other analysts have also recently weighed in on BGNE. 22nd Century Group reiterated a downgrade rating on […]